Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Just the Facts, Ma'am: A Compendium of Liberal Fiction -- Ignore unavailable to you. Want to Upgrade?

To: Peter Dierks who wrote (40142)	9/12/2005 2:10:10 AM
From: Solon	Read Replies (1) \| Respond to of 90947

"In the US, it takes so long to get drug to market that frequently there are only a couple of years left on the US patent by the time it is available. It compresses the window of opportunity to recover R&D costs." I DO buy stocks so I am somewhat familiar with the fact that ALL pharmaceutical initiatives require testing, etc. I have owned a Canadian Company for several years. INFLAZYME went through all the Necessaries and came up short. The shareholders (myself being one, as I said) are paying for the R&D. I think if the big Drug Dealers were being hard done by they would be quite poor. Is that fair comment, Peter?